Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
FINDEX Inc. (3649.T)
Tokyo, JP
FINDEX Inc., a company established in Tokyo in 1985, focuses on the creation, production, and distribution of medical technology systems across Japan. Their portfolio features Claio, a comprehensive medical imaging database management system utilized by hospitals of all sizes, and C-Note, a dedicated platform for managing patient progress notes. They also offer DocuMaker, a sophisticated document and data management solution engineered with various input tools to boost efficiency, and the GAP/GAP-screener, which is an advanced gaze analyzing perimeter. Additionally, FINDEX Inc. develops mobile applications for smartphones. Their services cater to a wide range of medical clients, including hospitals, clinics, and other healthcare institutions. The organization adopted its current name, FINDEX Inc., in November 2014, having previously operated as PSC Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.84% | -1.53% | -5.49% | -12.84% | -14.10% | -15.41% | +8.86% | +24.44% | -28.40% | -53.57% | +807.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+4.6% Q1'26: +2.0% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%+10.5% Q1'26: +2.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+25.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+29.3% ★ Q1'26: +40.4% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+33.9% ★ Q1'26: +52.1% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%-2.2% ★ Q1'26: -4.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.95B
est: 2.90B (+1.8%)
|
3.29B
est: 3.24B (+1.5%)
|
3.31B
est: 3.50B (-5.4%)
|
3.60B
est: 3.50B (+3.0%)
|
4.28B
est: 4.10B (+4.4%)
|
4.00B
est: 4.00B (+0.1%)
|
4.97B
est: 4.90B (+1.4%)
|
4.54B
est: 4.60B (-1.3%)
|
5.19B
est: 5.00B (+3.8%)
|
5.84B
est: 5.90B (-1.0%)
|
6.11B
est: 6.15B (-0.7%)
|
6.25B
6.25B – 6.25B
+1.6% YoY
|
7.07B
7.07B – 7.07B
+13.1% YoY
|
7.70B
7.70B – 7.70B
+8.9% YoY
|
| EBITDA |
976.42M
est: 817.47M (+19.4%)
|
1.07B
est: 913.31M (+17.5%)
|
923.80M
est: 986.60M (-6.4%)
|
1.00B
est: 986.60M (+1.4%)
|
1.17B
est: 1.16B (+1.1%)
|
1.02B
est: 1.13B (-9.8%)
|
1.23B
est: 1.38B (-11.0%)
|
1.28B
est: 1.30B (-1.0%)
|
1.75B
est: 1.41B (+24.5%)
|
1.82B
est: 2.59B (-29.8%)
|
2.10B
est: 2.70B (-22.2%)
|
2.74B
2.74B – 2.74B
+1.6% YoY
|
3.10B
3.10B – 3.10B
+13.1% YoY
|
3.38B
3.38B – 3.38B
+8.9% YoY
|
| EBIT |
670.29M
est: 660.84M (+1.4%)
|
724.66M
est: 738.32M (-1.8%)
|
546.24M
est: 797.57M (-31.5%)
|
592.97M
est: 797.57M (-25.7%)
|
743.01M
est: 934.29M (-20.5%)
|
636.28M
est: 911.51M (-30.2%)
|
920.36M
est: 1.12B (-17.6%)
|
1.03B
est: 1.05B (-1.9%)
|
1.50B
est: 1.14B (+31.3%)
|
1.53B
est: 2.36B (-35.4%)
|
1.79B
est: 2.46B (-27.3%)
|
2.50B
2.50B – 2.50B
+1.6% YoY
|
2.83B
2.83B – 2.83B
+13.1% YoY
|
3.08B
3.08B – 3.08B
+8.9% YoY
|
| Net Income |
441.40M
est: 325.90M (+35.4%)
|
499.92M
est: 451.64M (+10.7%)
|
366.63M
est: 546.59M (-32.9%)
|
398.02M
est: 379.79M (+4.8%)
|
499.25M
est: 487.56M (+2.4%)
|
430.46M
est: 438.81M (-1.9%)
|
636.03M
est: 721.08M (-11.8%)
|
722.78M
est: 569.68M (+26.9%)
|
1.06B
est: 921.24M (+15.0%)
|
1.16B
est: 1.08B (+7.9%)
|
1.26B
est: 1.24B (+1.4%)
|
1.36B
1.36B – 1.36B
+9.5% YoY
|
1.54B
1.54B – 1.54B
+13.7% YoY
|
1.90B
1.90B – 1.90B
+23.3% YoY
|
| SGA |
924.95M
est: 1.00B (-7.9%)
|
1.15B
est: 1.12B (+2.6%)
|
1.33B
est: 1.21B (+10.1%)
|
1.31B
est: 1.21B (+7.8%)
|
1.51B
est: 1.42B (+6.2%)
|
1.41B
est: 1.38B (+1.9%)
|
1.61B
est: 1.70B (-5.1%)
|
1.66B
est: 1.59B (+4.0%)
|
1.78B
est: 1.73B (+2.8%)
|
1.99B
est: 2.04B (-2.7%)
|
2.19B
est: 2.13B (+3.1%)
|
2.16B
2.16B – 2.16B
+1.6% YoY
|
2.45B
2.45B – 2.45B
+13.1% YoY
|
2.67B
2.67B – 2.67B
+8.9% YoY
|
| EPS |
17.00
est: 12.70 (+33.9%)
|
19.35
est: 17.60 (+9.9%)
|
14.21
est: 21.30 (-33.3%)
|
15.43
est: 14.80 (+4.3%)
|
19.50
est: 19.00 (+2.6%)
|
16.81
est: 17.10 (-1.7%)
|
24.84
est: 28.10 (-11.6%)
|
28.21
est: 22.20 (+27.1%)
|
41.31
est: 35.90 (+15.1%)
|
45.30
est: 42.90 (+5.6%)
|
50.07
est: 49.40 (+1.4%)
|
54.10
54.10 – 54.10
+9.5% YoY
|
61.50
61.50 – 61.50
+13.7% YoY
|
75.80
75.80 – 75.80
+23.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.00% | 25.5K | 0.45% |
| 2 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 1.06M | 0.03% |
| 3 | Dimensional - International Small Cap ETF DFIS | 0.00% | 125.4K | 0.39% |
| 4 | iShares Core TOPIX ETF 1475.T | 0.00% | 212.1K | 0.05% |
| 5 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 100.6K | 0.22% |
| 6 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 1.7K | 0.30% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 58.9K | 0.28% |
| 8 | Avantis International Equity ETF AVDE | 0.00% | 16.8K | 0.23% |
| 9 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chikara Miyagawa | Head of Information Security & Director | — | male |
| Hiroaki Hasegawa | Director of Consulting & Director | — | male |
| Keisuke Kakiuchi | Head of Hospital Solutions & Director | — | — |
| Koji Kondo | Medical Solutions Manager & Director | — | male |
| Takahiro Yazawa | Finance & Investor Relations Officer and Director | — | — |
| Teruo Aibara | Chief Executive Officer, President & Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3649.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
